Yamanouchi's Foray Into Drug Delivery
Executive Summary
Yamanouchi attempts to use its drug delivery business (Yamanouchi Shaklee Pharma) to help jumpstart its efforts to gain a foothold in the US and to eventually become a true global player. Yamanouchi's support of YSP may, however, be a two-edged sword: it provides YSP with the kind of financial support that most drug delivery companies can only dream of, but it may also scare off potential partners.
You may also be interested in...
Tanabe and Taisho Get Big in Japan
Two of Japan's largest pharmaceutical companies, Tanabe Seiyaku and Taisho Pharmaceutical, are merging in response to hard times in the Japanese pharma industry. Their union, which will take at least a year to complete, will create a combined company with $4.3 billion in sales, ranking it third in Japan in revenues. The move won't solve both companies' weak pipeline problems, but it will increase their total R&D budget and give them more sales clout in the domestic market. And as many Japanese pharma companies struggle for survival, analysts believe more merger activity is inevitable.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.